Relationship between MMP-9 serum levels and tHcy levels and total imaging load and cognitive dysfunction

被引:15
|
作者
Zhao, Jianhua [1 ]
Li, Qiong [1 ]
Meng, Lifang [2 ]
Wang, Fan [1 ]
Li, Qing [1 ]
Yang, Fangli [1 ]
Wang, Minghua [1 ]
Yu, Miao [1 ]
Zhang, Jian [3 ]
Li, Shaomin [4 ]
Ji, Sibei [1 ]
机构
[1] Xinxiang Med Univ, Affiliated Hosp 1, Henan Joint Int Res Lab Neurorestoratol Senile Dem, Henan Key Lab Neurorestoratol, Xinxiang 453100, Henan, Peoples R China
[2] Kaifeng Pepoples Hosp, Neurol, Kaifeng 475000, Henan, Peoples R China
[3] Xinxiang Med Univ, Affiliated Hosp 1, Imaging Dept, Xinxiang 453100, Henan, Peoples R China
[4] Harvard Med Sch, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA
来源
关键词
MMP-9; Cognitive function; Total imaging load; Cerebral small vessel disease; SMALL VESSEL DISEASE; MATRIX METALLOPROTEINASES; MRI;
D O I
10.1016/j.jstrokecerebrovasdis.2022.106759
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Objectives: To investigate the correlation and predictive value of serum matrix met-alloproteinase-9 (MMP-9) level with cognitive dysfunction and total imaging load in patients with cerebral small vessel disease (CSVD). Methods: A total of 80 patients with CSVD who were admitted to the First Affiliated Hospital of Xinxiang Medical University between April 2019 and April 2020 were enrolled. All subjects under-went T1-weighted imaging (T1WI), T2WI, fluid-attenuated inversion recovery (FLAIR), diffusion weighted imaging (DWI), serum sample collection, and assess-ment of cognitive function at a specific time-point after admission. According to the results of the neuropsychological test, subjects were divided into cognitive dysfunc-tion group (n=40) and normal cognitive function group (n=40). The total imaging load was estimated according to the neuroimaging findings. Serum MMP-9 level was measured by an enzyme-linked immunosorbent assay (ELISA) kit. Beside, serum MMP-9 level and total imaging load were compared between the two groups. Results: Serum levels of MMP-9 and plasma total homocysteine (tHcy) were negatively correlated with cognitive function (P<0.05). Serum MMP-9 level was found as a significant factor for diagnosing cognitive impairment due to CSVD (area under the curve (AUC), 0.756; sensitivity and specificity were 97.5% and 75.0%, respectively). THcy level was also found as significant factor for diagnosing cognitive impairment due to CSVD (area under the curve (AUC), 0.727; sensitivity and specificity were 97.5% and 75.0%, respectively). Conclusion: Serum MMP-9 level and tHcy level were significantly correlated with cognitive function in patients with CSVD. Serum MMP-9 level has a specific correlation with the total imaging load in patients with CSVD. It plays an important role in diagnosing cognitive impairment in patients with CSVD.(c) 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Elevated serum levels of VEGF, bFGF, MMP-2, and MMP-9 in patients with Moyamoya disease
    Lim, M
    Wang, Y
    Bower, R
    Cheshier, S
    Sims, L
    Choi, S
    Harsh, G
    Steinberg, G
    Guccione, S
    STROKE, 2006, 37 (02) : 701 - 701
  • [32] CHANGES OF SERUM LEVELS OF MMP-2, MMP-9 AND ITS INHIBITOR IN NEONATAL INTRACRANIAL HEMORRHAGE
    Wang, J.
    Zhang, L. H.
    Wang, X. H.
    Kang, X. M.
    Meng, Q. Y.
    Nie, J.
    Chen, W. H.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 119 : 29 - 29
  • [33] Specific matrix metalloproteinase 9 (MMP-9) haplotype affect the circulating MMP-9 levels in women with migraine
    Martins-Oliveira, Alisson
    Goncalves, Flavia M.
    Speciali, Jose G.
    Fontana, Vanessa
    Izidoro-Toledo, Tatiane C.
    Belo, Vanessa A.
    Dach, Fabiola
    Tanus-Santos, Jose E.
    JOURNAL OF NEUROIMMUNOLOGY, 2012, 252 (1-2) : 89 - 94
  • [34] Serum S100A8/A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment
    Munoz-Grajales, Carolina
    Barraclough, Michelle L.
    Diaz-Martinez, Juan P.
    Su, Jiandong
    Bingham, Kathleen
    Kakvan, Mahta
    Kretzmann, Roberta Pozzi
    Tartaglia, Maria Carmela
    Ruttan, Lesley
    Choi, May Y.
    Appenzeller, Simone
    Marzouk, Sherief
    Bonilla, Dennisse
    Katz, Patricia
    Beaton, Dorcas
    Green, Robin
    Gladman, Dafna D.
    Wither, Joan
    Touma, Zahi
    FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [35] Does metabolic status affect serum levels of BDNF and MMP-9 in patients with schizophrenia?
    Arabska, Jasmina
    Margulska, Aleksandra
    Strzelecki, Dominik
    Wysokinski, Adam
    NORDIC JOURNAL OF PSYCHIATRY, 2019, 73 (08) : 515 - 521
  • [36] Childhood Obesity, MMP-9 Levels, and Vitamin D
    Cerit, Zeynep
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2017, 109 (04) : 380 - 380
  • [37] ASSESSMENT OF SERUM MMP-9, TIMP-1 LEVELS AND MMP-9/TIMP-1 RATIO IN MIGRAINE PATIENTS WITH AND WITHOUT AURA
    Karademir, Fazilet
    Ozturk, Musa
    Altunkaynak, Yavuz
    Doventas, Yasemin
    Mutluay, Belgin
    Koseahmet, Fulya Basoglu
    Baybas, Sevim
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2022, 75 (9-10): : 341 - 349
  • [38] Relationship between the Levels of MMP-9, TIMP-1, and Zinc in Biological Samples of Patients with Carotid Atherosclerosis
    Usmanova, Zakhro A.
    INTERNATIONAL JOURNAL OF BIOMEDICINE, 2015, 5 (02) : 60 - 64
  • [39] The Clinical Effect of Electroconvulsive Therapy and Its Relationship with Serum Levels of MMP-9 and CXCL12 in Patients with Mania
    Kashefi, Babak
    Mohammadi, Mehdi
    Rezaei, Farzin
    Ghadami, Narges
    Jalili, Khashaiar
    Jalili, Ali
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2020, 16 : 909 - 914
  • [40] Plasma levels of matrix metalloproteinase-9 (MMP-9) are associated with cognitive performance in patients with schizophrenia
    Kudo, Noriko
    Yamamori, Hidenaga
    Ishima, Tamaki
    Nemoto, Kiyotaka
    Yasuda, Yuka
    Fujimoto, Michiko
    Azechi, Hirotsugu
    Niitsu, Tomihisa
    Numata, Shusuke
    Ikeda, Manabu
    Iyo, Masaomi
    Ohmori, Tetsuro
    Fukunaga, Masaki
    Watanabe, Yoshiyuki
    Hashimoto, Kenji
    Hashimoto, Ryota
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2020, 40 (02) : 150 - 156